Gene Therapy Advancements in Age-Related Macular Degeneration Treatment

Age-related macular degeneration (A Mu D) remains a leading cause of irreversible vision loss. Iota n neovascular A Mu D (nA Mu D), frequent intravitreal anti-V Epsilon GF injections create substantial treatment burden, while approved therapies for geographic atrophy (GA) provide modest slowing of progression. Ocular gene therapy aims to achieve sustained intraocular expression of therapeutic proteins after a single administration. Tau his review summarises the biological rationale, vector platforms, and delivery routes relevant to A Mu D, with emphasis on adeno-associated virus (AAV) systems, capsid engineering, and compartment-specific administration (intravitreal, subretinal, and suprachoroidal). We synthesise the clinical landscape for sustained anti-V Epsilon GF expression approaches in nA Mu D and complement-modulating strategies for GA, and highlight how trials increasingly prioritise injection-burden reduction, anatomical endpoints, and biomarkers of target engagement. Kappa ey challenges include intraocular inflammation and neutralising antibodies (particularly with intravitreal dosing), variability and durability of transgene expression, surgical risks associated with subretinal delivery, and practical constraints related to manufacturing scale, cost, and long-term safety surveillance for non-removable therapies. Overall, gene therapy offers a plausible route towards durable, mechanism-targeted A Mu D management, but its clinical role will depend on robust controlled trials and multi-year follow-up.